The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention
Resource type
Journal Article
Authors/contributors
- Little, Jessica S (Author)
- Kampouri, Eleftheria (Author)
- Friedman, Daniel Z (Author)
- McCarty, Todd (Author)
- Thompson, George R (Author)
- Kontoyiannis, Dimitrios P (Author)
- Vazquez, Jose (Author)
- Baddley, John W (Author)
- Hammond, Sarah P (Author)
Title
The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention
Abstract
Abstract
Chimeric antigen receptor (CAR) T-cell therapy is a novel immunotherapy approved for the treatment of hematologic malignancies. This therapy leads to a variety of immunologic deficits that could place patients at risk for invasive fungal disease (IFD). Studies assessing IFD in this setting are limited by inconsistent definitions and heterogeneity in prophylaxis use, although the incidence of IFD after CAR T-cell therapy, particularly for lymphoma and myeloma, appears to be low. This review evaluates the incidence of IFD after CAR T-cell therapy, and discusses optimal approaches to prevention, highlighting areas that require further study as well as future applications of cellular therapy that may impact IFD risk. As the use of CAR T-cell therapy continues to expand for hematologic malignancies, solid tumors, and most recently to include non-oncologic diseases, understanding the risk for IFD in this uniquely immunosuppressed population is imperative to prevent morbidity and mortality.
Publication
Open Forum Infectious Diseases
Volume
11
Issue
6
Pages
ofae133
Date
2024-06-03
Language
en
ISSN
2328-8957
Accessed
7/9/24, 8:10 PM
Library Catalog
DOI.org (Crossref)
Citation
Little, J. S., Kampouri, E., Friedman, D. Z., McCarty, T., Thompson, G. R., Kontoyiannis, D. P., Vazquez, J., Baddley, J. W., & Hammond, S. P. (2024). The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention. Open Forum Infectious Diseases, 11(6), ofae133. https://doi.org/10.1093/ofid/ofae133
HEME-ONC AND CELLULAR THERAPIES
Link to this record